I suspect they are running parallel in vitro and animal models - as much as they can under the umbrella of R&D. I also feel confident that they have pored over all statistical parameters looking for weakness. Yes, all pharmas would do the same, and many many drugs fail PIII. The big difference with Arikace is that the endpoints are attainable and have been seen with good stats in earlier studies. Unlike earlier Insmed failures with GA - WL is far more the businessman than GA, RIP, ever was. WL also does not have the hubris that GA sometimes would project. All this goes to a far better understanding of what the FDA needs to see in order to proceed.
We'll know in the next few weeks how this all plays out.
"data out shortly", but then said the company will take the time to get the data analysis correct.
No questions ( breakout only)
Nice call- Will sounds confident, but as biotech investors have so often learned....don't bet the farm..